The first clinical study of Sangamo Biosciences Inc.’s (Nasdaq: SGMO) zinc finger nuclease-based genome editing technology in humans was published in the New England Journal of Medicine. The stock price jumped $3.60 to $23.22.
Study Of Sangamo’s Technology Published
March 06, 2014 at 05:44 AM EST
